616 related articles for article (PubMed ID: 25905680)
1. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
[TBL] [Abstract][Full Text] [Related]
2. Combinational PRR Agonists in Liposomal Adjuvant Enhances Immunogenicity and Protective Efficacy in a Tuberculosis Subunit Vaccine.
Hao L; Wu Y; Zhang Y; Zhou Z; Lei Q; Ullah N; Banga Ndzouboukou JL; Lin X; Fan X
Front Immunol; 2020; 11():575504. PubMed ID: 33117374
[TBL] [Abstract][Full Text] [Related]
3. Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells.
Wang X; Zhang J; Liang J; Zhang Y; Teng X; Yuan X; Fan X
PLoS One; 2015; 10(3):e0122560. PubMed ID: 25822536
[TBL] [Abstract][Full Text] [Related]
4. Differential Immunogenicity and Protective Efficacy Elicited by MTO- and DMT-Adjuvanted CMFO Subunit Vaccines against
Ullah N; Hao L; Wu Y; Zhang Y; Lei Q; Banga Ndzouboukou JL; Lin X; Fan X
J Immunol Res; 2020; 2020():2083793. PubMed ID: 32953889
[TBL] [Abstract][Full Text] [Related]
5. Formulation in DDA-MPLA-TDB Liposome Enhances the Immunogenicity and Protective Efficacy of a DNA Vaccine against
Tian M; Zhou Z; Tan S; Fan X; Li L; Ullah N
Front Immunol; 2018; 9():310. PubMed ID: 29535714
[TBL] [Abstract][Full Text] [Related]
6. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
[TBL] [Abstract][Full Text] [Related]
7. Heterologous Boost Following
Wu Y; Cai M; Ma J; Teng X; Tian M; Bassuoney EBMB; Fan X
Front Immunol; 2018; 9():2439. PubMed ID: 30425711
[TBL] [Abstract][Full Text] [Related]
8. Enhanced immunogenicity of the tuberculosis subunit Rv0572c vaccine delivered in DMT liposome adjuvant as a BCG-booster.
Mao L; Xu L; Wang X; Xing Y; Wang J; Zhang Y; Yuan W; Du J; Shi Z; Ma J; Zhang J; Zhang X; Wang X
Tuberculosis (Edinb); 2022 May; 134():102186. PubMed ID: 35245739
[TBL] [Abstract][Full Text] [Related]
9. A Multistage Subunit Vaccine Effectively Protects Mice Against Primary Progressive Tuberculosis, Latency and Reactivation.
Ma J; Teng X; Wang X; Fan X; Wu Y; Tian M; Zhou Z; Li L
EBioMedicine; 2017 Aug; 22():143-154. PubMed ID: 28711483
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of Th1-Type Immune Responses to
Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG
J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214
[TBL] [Abstract][Full Text] [Related]
11. Mycobacterium tuberculosis multistage antigens confer comprehensive protection against pre- and post-exposure infections by driving Th1-type T cell immunity.
Ma J; Tian M; Fan X; Yu Q; Jing Y; Wang W; Li L; Zhou Z
Oncotarget; 2016 Sep; 7(39):63804-63815. PubMed ID: 27566581
[TBL] [Abstract][Full Text] [Related]
12. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
13. Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection.
Trentini MM; de Oliveira FM; Gaeti MP; Batista AC; Lima EM; Kipnis A; Junqueira-Kipnis AP
Vaccine; 2014 Jul; 32(34):4324-32. PubMed ID: 24951861
[TBL] [Abstract][Full Text] [Related]
14. Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX.
Niu H; Hu L; Li Q; Da Z; Wang B; Tang K; Xin Q; Yu H; Zhang Y; Wang Y; Ma X; Zhu B
Vaccine; 2011 Nov; 29(51):9451-8. PubMed ID: 22024175
[TBL] [Abstract][Full Text] [Related]
15. PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection.
Ashhurst AS; Parumasivam T; Chan JGY; Lin LCW; Flórido M; West NP; Chan HK; Britton WJ
PLoS One; 2018; 13(3):e0194620. PubMed ID: 29554138
[TBL] [Abstract][Full Text] [Related]
16. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
17. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
[TBL] [Abstract][Full Text] [Related]
19. A multistage mycobacterium tuberculosis subunit vaccine LT70 including latency antigen Rv2626c induces long-term protection against tuberculosis.
Liu X; Peng J; Hu L; Luo Y; Niu H; Bai C; Wang Q; Li F; Yu H; Wang B; Chen H; Guo M; Zhu B
Hum Vaccin Immunother; 2016 Jul; 12(7):1670-7. PubMed ID: 26901244
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and protective efficacy of novel Mycobacterium tuberculosis antigens.
Derrick SC; Yabe IM; Yang A; Kolibab K; Hollingsworth B; Kurtz SL; Morris S
Vaccine; 2013 Sep; 31(41):4641-6. PubMed ID: 23906890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]